Abstract Body

In HIV, the prevalence of zinc deficiency appears to be high and low plasma zinc levels have been linked with disease progression and an increased risk of death. In this study, we explored the effect of zinc supplementation on the heightened state of inflammation and monocyte activation observed in ART-treated HIV infection.

This is a pilot open labeled randomized double arm study, studying the efficacy and safety of zinc therapy on inflammation in ≥ 18 years old HIV-infected patients , on stable ART (for at least 12 weeks) and with zinc levels ≤75 µg/dL in the last 60 days. Patients were randomized 1:1 to zinc gluconate capsules at a dose of 45mg (low-dose), or 90mg (high-dose) elemental zinc daily for 16 weeks. We assessed the following markers at baseline and 16 weeks: high sensitivity C reactive protein (hsCRP), soluble CD14 (sCD14), soluble tumor necrosis alpha receptor I and II (sTNFR-I and II), lipopolysaccharide binding protein (LBP) and intestinal fatty acid binding protein (IFABP). We performed significance tests for the shift of distributions using Kolmogorov –Smironow test. Effect size was reported as Cohen’s d.

Overall, a total of 52 participants were enrolled (25 participants in the low-dose arm and 27 participants in the high-dose arm). Mean age was 49 years, 77% were males and 73% were African Americans. At baseline, mean zinc levels were 75 µg/dL. After 16 weeks, loss to follow up was minimal with 92% retention. One patient developed nausea possibly related to the zinc capsules, there were no other study related adverse events. Mean circulating zinc levels increased to 91 µg/dL in the low-dose arm and to 105 µg/dL in the high-dose arm. In addition, 88% of participants in the low-dose arm and 96% in the high-dose arm reached zinc levels >75 µg/dL. Overall, biomarkers decreased with a margin of reduction ranging between 8 and 33% (figure 1). There was a larger margin of change in sCD14 and IFABP in the participants in the low-dose arm, however the reductions were greater for hsCRP and LBP in the high-dose arm. This change was meaningful with large effect size (Cohen’s ranging from 5-19).

In this pilot study we found that zinc supplementation is safe and effective at increasing circulating zinc levels. In addition our findings provide novel data that zinc can impact a biological signature in patients with HIV and modulate biomarkers that have been associated with clinical comorbidities.